Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Invited discussant LBA45, LBA47_PR and abstract 1202O

Date

10 Oct 2016

Session

NSCLC, metastatic 2

Presenters

Tony S.K. Mok

Authors

T.S.K. Mok

Author affiliations

Clinical Oncology, The Chinese University of Hong Kong, NA - Hong Kong/CN

More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

10 Oct 2016

Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer

Presenter: David Spigel

Session: NSCLC, metastatic 2

Resources:

Abstract

Slides

10 Oct 2016

Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial

Presenter: Pasi Jänne

Session: NSCLC, metastatic 2

Resources:

Abstract

Slides

10 Oct 2016

Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Presenter: Charlotte Leduc

Session: NSCLC, metastatic 2

Resources:

Abstract